Allogene Therapeutics (ALLO) Cash from Operations (2018 - 2026)

Allogene Therapeutics has reported Cash from Operations for 9 years, with the latest figure at 12913000.0 in Q1 2026.

• Quarterly Cash from Operations rose 75.6% year-over-year to 12913000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 109230000.0 (up 44.65% YoY) and the FY2025 annual result came in at 149246000.0, up 25.49% from the prior year.
• Cash from Operations rose to 12913000.0 in Q1 2026 per ALLO's latest filing, from 27599000.0 in the prior quarter.
• Over five years, Cash from Operations peaked at 12913000.0 in Q1 2026 and troughed at 68237000.0 in Q1 2022.
• A 5-year average of 48277117.65 and a median of 52929000.0 in 2025 frame the typical range for Cash from Operations.
• The sharpest annual moves came in 2023 and 2026: Cash from Operations plunged 45.44% in 2023, then surged 75.6% in 2026.
• Over 5 years, Cash from Operations stood at 62096000.0 in 2022, then advanced by 13.51% to 53707000.0 in 2023, then soared by 31.67% to 36698000.0 in 2024, then rose by 24.79% to 27599000.0 in 2025, then soared by 53.21% to 12913000.0 in 2026.
• According to Business Quant data, Cash from Operations over the past three periods registered 12913000.0, 27599000.0, and 29688000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.